A new study presented at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona reveals that combining chemotherapy with either cetuximab or bevacizumab provided equivalent survival in patients suffering from KRAS wild-type untreated colorectal cancer. "The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study was designed to determine if one was better ...Sunday, 29 June 2014
Combining Chemotherapy With Cetuximab or Bevacizumab Provides Same Benefit for KRAS Wild-Type MCRC Patients
A new study presented at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona reveals that combining chemotherapy with either cetuximab or bevacizumab provided equivalent survival in patients suffering from KRAS wild-type untreated colorectal cancer. "The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study was designed to determine if one was better ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment